Details of the Drug Combination

General Information of Drug Combination (ID: DC6LYSZ)

Drug Combination Name
BIO-300 Bendamustine hydrochloride
Indication
Disease Entry Status REF
Breast adenocarcinoma Investigative [1]
Component Drugs BIO-300   DMJ7NVI Bendamustine hydrochloride   DMFH15Z
N.A. Small molecular drug
High-throughput Screening Result Testing Cell Line: MDA-MB-468
Zero Interaction Potency (ZIP) Score: 4.19
Bliss Independence Score: 7.25
Loewe Additivity Score: 3.6
LHighest Single Agent (HSA) Score: 10.4

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of BIO-300
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
Rheumatoid arthritis FA20 Phase 1 [3]
Indication(s) of Bendamustine hydrochloride
Disease Entry ICD 11 Status REF
leukaemia 2A60-2B33 Approved [4]
Bendamustine hydrochloride Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [4]
------------------------------------------------------------------------------------
Bendamustine hydrochloride Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [6]
------------------------------------------------------------------------------------
Bendamustine hydrochloride Interacts with 6 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [5]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [5]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Expression [7]
PRKC apoptosis WT1 regulator protein (PAWR) OTKY7W52 PAWR_HUMAN Decreases Expression [5]
Diablo IAP-binding mitochondrial protein (DIABLO) OTHJ9MCZ DBLOH_HUMAN Increases Localization [5]
Death domain-associated protein 6 (DAXX) OTX6O7PL DAXX_HUMAN Decreases Expression [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult T acute lymphoblastic leukemia DCMYOIZ MOLT-4 Investigative [8]
Anaplastic large cell lymphoma DC8J3L7 SR Investigative [8]
Astrocytoma DC03HBQ SNB-19 Investigative [8]
Childhood T acute lymphoblastic leukemia DCD71RM CCRF-CEM Investigative [8]
Chronic myelogenous leukemia DCT6R7A K-562 Investigative [8]
Glioma DC7RL2B SF-539 Investigative [8]
Glioma DCPD8LK SF-268 Investigative [8]
Papillary renal cell carcinoma DCLWPYT ACHN Investigative [8]
Plasma cell myeloma DCDD94C RPMI-8226 Investigative [8]
Renal cell carcinoma DCZBXNF UO-31 Investigative [8]
Carcinoma DCKAVL0 RXF 393 Investigative [1]
Colon adenocarcinoma DC695SI COLO 205 Investigative [1]
Invasive ductal carcinoma DCWD8MG HS 578T Investigative [1]
Invasive ductal carcinoma DCTPF96 BT-549 Investigative [1]
Adenocarcinoma DCUUA2Q DU-145 Investigative [9]
Adenocarcinoma DCPSVKC OVCAR3 Investigative [9]
Adenocarcinoma DCTI5RQ NCIH23 Investigative [9]
Adenocarcinoma DC6BYV9 A549 Investigative [9]
Adenocarcinoma DCP9C07 SW-620 Investigative [9]
Adenocarcinoma DCRXGG7 HCT116 Investigative [9]
Adenocarcinoma DCCIQPG HCC-2998 Investigative [9]
Adenocarcinoma DC9PG7A HCT-15 Investigative [9]
Adenocarcinoma DCYUDI0 HT29 Investigative [9]
Cutaneous melanoma DCZGLTG SK-MEL-28 Investigative [9]
High grade ovarian serous adenocarcinoma DCEHGSK OVCAR-5 Investigative [9]
High grade ovarian serous adenocarcinoma DC7UDR7 OVCAR-4 Investigative [9]
High grade ovarian serous adenocarcinoma DCR1YRN OVCAR-8 Investigative [9]
Large cell lung carcinoma DCBZVS8 NCI-H460 Investigative [9]
Lung adenocarcinoma DCZIBN3 NCI-H522 Investigative [9]
Melanoma DCKW0CO MALME-3M Investigative [9]
Minimally invasive lung adenocarcinoma DCIADZT NCI-H322M Investigative [9]
Prostate carcinoma DCNSDSE PC-3 Investigative [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 32 DrugCom(s)

References

1 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1126165
2 Clinical pipeline report, company report or official report of Humanetics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
5 Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol. 2003 Sep 1;66(5):711-24. doi: 10.1016/s0006-2952(03)00410-6.
6 Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites. Cancer Chemother Pharmacol. 2015 Jun;75(6):1143-54.
7 Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus. Leuk Lymphoma. 2004 Jul;45(7):1429-36. doi: 10.1080/1042819042000198858.
8 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125966
9 CheMBL Affinity Phenotypic Cellular Interaction Assay ID: CHEMBL1125976